Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fadi Braiteh

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
The Oncologist|May 17, 2017
Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNAAndrea Z Lai, Alexa B Schrock, Rachel L Erlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2020
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue SarcomaSant P Chawla, Sanjay Goel, Warren Chow, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumorsDing Wang, Fadi Braiteh, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersFadi Braiteh, Andres O Soriano, Guillermo Garcia-Manero, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Oncotarget|November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm studySarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
Cancer|June 30, 2009
Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapyFadi Braiteh, Arlene M Correa, Wayne L Hofstetter, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
The Oncologist|May 17, 2017
Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNAAndrea Z Lai, Alexa B Schrock, Rachel L Erlich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2020
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue SarcomaSant P Chawla, Sanjay Goel, Warren Chow, et al.
Targeted Oncology|October 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of AdministrationSiwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson, et al.
JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumorsDing Wang, Fadi Braiteh, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersFadi Braiteh, Andres O Soriano, Guillermo Garcia-Manero, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Oncotarget|November 20, 2019
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm studySarina A Piha-Paul, Matthew H Taylor, Daniel Spitz, et al.
Cancer|June 30, 2009
Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapyFadi Braiteh, Arlene M Correa, Wayne L Hofstetter, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancerZorawar S Noor, Jonathan W Goldman, William E Lawler, et al.
Pageof 7